Search research articles
Contact Us
Filters
Showing results (631-640 of 692) with videos related to
Page
of 70
Sort By:
The Lancet. Oncology
|
November 20, 2016
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data
Justin Guinney, Tao Wang, Teemu D Laajala, et al.
Medrxiv : the Preprint Server for Health Sciences
|
September 24, 2024
Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancer
Casey R Ager, Aleksandar Obradovic, Patrick McCann, et al.
Open Forum Infectious Diseases
|
July 28, 2022
An Analysis of SARS-CoV-2 Vaccine Reactogenicity: Variation by Type, Dose, and History, Severity, and Recency of Prior SARS-CoV-2 Infection
Ann I Scher, Catherine M Berjohn, Celia Byrne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2021
Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer
Jamie M Sperger, Hamid Emamekhoo, Rana R McKay, et al.
The Lancet. Oncology
|
May 17, 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D Kwon, Charles G Drake, Howard I Scher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 14, 2019
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
Andrew J Armstrong, Susan Halabi, Jun Luo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 16, 2015
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
Neeta Pandit-Taskar, Joseph A O'Donoghue, Jeremy C Durack, et al.
Cell Reports. Medicine
|
February 27, 2026
Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial
Casey R Ager, Aleksandar Obradovic, Patrick McCann, et al.
The New England Journal of Medicine
|
June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapy
Tomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 2024
Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Andrew T Lenis, Vignesh Ravichandran, Samantha Brown, et al.
Page
of 70
Search research articles
Search
Showing results (631-640 of 692) with videos related to
Sort By:
Page
of 70
The Lancet. Oncology
|
November 20, 2016
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data
Justin Guinney, Tao Wang, Teemu D Laajala, et al.
Medrxiv : the Preprint Server for Health Sciences
|
September 24, 2024
Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancer
Casey R Ager, Aleksandar Obradovic, Patrick McCann, et al.
Open Forum Infectious Diseases
|
July 28, 2022
An Analysis of SARS-CoV-2 Vaccine Reactogenicity: Variation by Type, Dose, and History, Severity, and Recency of Prior SARS-CoV-2 Infection
Ann I Scher, Catherine M Berjohn, Celia Byrne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2021
Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer
Jamie M Sperger, Hamid Emamekhoo, Rana R McKay, et al.
The Lancet. Oncology
|
May 17, 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D Kwon, Charles G Drake, Howard I Scher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 14, 2019
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
Andrew J Armstrong, Susan Halabi, Jun Luo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 16, 2015
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
Neeta Pandit-Taskar, Joseph A O'Donoghue, Jeremy C Durack, et al.
Cell Reports. Medicine
|
February 27, 2026
Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial
Casey R Ager, Aleksandar Obradovic, Patrick McCann, et al.
The New England Journal of Medicine
|
June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapy
Tomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 2024
Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Andrew T Lenis, Vignesh Ravichandran, Samantha Brown, et al.
Page
of 70